Published in Medical Letter on the CDC and FDA, March 21st, 2004
Used in the prevention of hemolytic disease of the fetus and newborn (HDN), Rhophylac provides a choice for physicians and patients who are concerned about the pain associated with IM administration, especially when multiple injections are required.
ZLB Bioplasma manufactures Rhophylac using the distinctive ChromaPlus process, which results in a highly pure therapeutic product that makes it possible to administer the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.